Human parainfluenza virus type 3 (HPIV-3) proteins (HPIV-3 proteins)

Human parainfluenza virus type 3 (HPIV-3) proteins are the essential structural and functional components of a major respiratory pathogen that causes significant morbidity in children and immunocompromised adults (StatPearls, NCBI). The viral proteome consists of six structural proteins: Nucleocapsid (N), Phosphoprotein (P), Matrix (M), Fusion (F), Hemagglutinin-neuraminidase (HN), and the Large (L) protein (UniProt). The HN and F proteins are surface glycoproteins responsible for viral attachment to sialic acid receptors and subsequent membrane fusion, making them primary targets for entry inhibitors (PubMed). The L protein functions as an RNA-dependent RNA polymerase, which, together with the P protein, facilitates viral genome replication and transcription (ViralZone). Currently, there are no FDA-approved vaccines or specific antivirals for HPIV-3, although ribavirin is occasionally used off-label for severe cases (PubMed). Investigational therapies like DAS181 (Fludase) target the host's sialic acid receptors to prevent HN-mediated attachment, while other research focuses on small molecules that inhibit the F protein or the L protein's polymerase activity (ClinicalTrials.gov). These proteins are critical for the viral life cycle, and their conservation across strains makes them attractive candidates for therapeutic intervention.

Other names

HPIV3Human respirovirus 3Parainfluenza 3HPIV-3

Inhibition of viral RNA-dependent RNA polymerase; Cleavage of host cell sialic acid receptors; Inhibition of viral membrane fusion.